Isolated Recurrent Lower Limb Deep Vein Thrombosis: A Rare Presentation of Paroxysmal Nocturnal Hemoglobinuria
Back to listIntroduction
Paroxysmal nocturnal hemoglobinuria (PNH) is an uncommon disease. Overall estimated prevalence of PNH is less than 1 in 100000. It is an acquired stem cell disorder characterized by chronic hemolytic anemia due to intravascular hemolysis, nocturnal hemoglobinuria, thrombosis, and pancytopenia.1 The PNH has been reported in all ages from 1 to 72 years but most common in young adults.
Abstract
Paroxysmal nocturnal hemoglobinuria(PNH) is an uncommon disease. Overall estimated prevalence of PNH is less than 1 in 100000. It is acquired stem cell disorder characterized by chronic hemolytic anemia due to intravascular hemolysis, nocturnal hemoglobinuria, thrombosis and pancytopenia-Non malignant clonal expansion of hematopoetic stem cells having acquired mutation of phosphatidylinositol glycan complementation class A gene (PIG-A) is the basic molecular defect.Thrombosis of visceral veins is common in PNH. Hepatic veins are commonly involved presenting as Budd Chiari Syndrome. Arterial thrombosis can also occur that lead to cerebral infarct. We evaluated a patient who was suffering from recurrent deep vein thrombosis (DVT) of left lower limb which is a rarely reported presentation of PNH.
Keywords
paroxysmal nocturnal hemoglobinuria, deep vein thrombosis, thrombophilia
Other Articles
- Effect of Adjusted and Non-Adjusted Citrate Concentrations on Coagulation Test Results in Patients With High Hematocrit Values—Breaking the Unproven Leap of Faith
- The Off-Label Use of Recombinant FVIIa in the Treatment of a Patient With T-Cell Non-Hodgkin Lymphoma Who Developed Intra-abdominal and Intra-Pleural Hemorrhages Followed by High-Dose Methotreaxate Therapy
- Prophylaxis with Once, Twice or Three-Times Weekly Dosing of rFVIII-FS prevents Joint Bleeds in a Previously Treated Pediatric Population with Moderate/Severe Hemophilia A
- Current Practice in Clinical Thrombosis and Hemostasis
- Review of the Literature of FEIBA Administration in Patients with Hemophilia B and Inhibitors
